Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 induction study of RPC1063 in moderately to severely active ulcerative colitis
2012-003123-38Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ozanimod in autoimmune colitis (4 arms), sponsored by Celgene Corporation. Primary endpoint: Clinical remission at Week 8. Started Oct 2012; status: completed.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2012-003123-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003123-38.